Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00166426 · ClinicalTrials.gov registry record · Phase 2
Exisulind Versus Placebo After Surgical Removal of the Prostate
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
NCT00166426: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT00166426 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 240 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00166426, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
Study Summary
This is a study in which patients with prostate cancer treated by surgical removal of the prostate and considered to be at risk for prostate cancer recurrence will receive Exisulind 250 mg twice a day or placebo twice a day for two years.
Interventions
- DRUG Exisulind
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2003-02 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00166426
The ClinicalTrials.gov registry entry for NCT00166426 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Exisulind is the first listed.
NCT00166426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00166426 about?
NCT00166426 is a clinical study titled "Exisulind Versus Placebo After Surgical Removal of the Prostate". This is a study in which patients with prostate cancer treated by surgical removal of the prostate and considered to be at risk for prostate cancer recurrence will receive Exisulind 250 mg twice a day or placebo twice a day for two years.
What is the current status of trial NCT00166426?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2003-02. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00166426?
The interventions under investigation include: Exisulind (DRUG).
Who is sponsoring clinical trial NCT00166426?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.